All posts by: Michael Zand

About Michael Zand

Supplement: Who Gets Immunotherapy for Cancer? – Genetic Engineering & Biotechnology News

Continue reading

2018-03-29 NEWS

Genetic Engineering & Biotechnology News

Supplement: Who Gets Immunotherapy for Cancer?
Genetic Engineering & Biotechnology News
Immunotherapy is an emerging field, and scientists are still learning how a patient’s immune repertoire and target profile translate to progression-free survival or disease remission. The immuno-oncology biomarkers, and companion diagnostics track at
Loncar Cancer Immunotherapy ETF – Receive News & Ratings DailyFrisco Fastball
Cancer Immunotherapy Market Experts Share 2016 Highlights, 2024 PredictionsEdition of Analyst

all 7 news articles »

Continue reading

2018-03-29 NEWS

American Council on Science and Health

CRISPR Science Prevails; Critics Proven ‘Off-Target’
American Council on Science and Health
New scientific discoveries should be held to a high standard. When they happen to be incredibly powerful and have the ability to edit the human genome, they should be held to the highest standard. It was not surprising then, that a paper published last